fbpx

Weekly Top News – Psoriasis – July 29, 2019

July 30, 2019

bimekizumab (UCB4940) / UCB
Bimekizumab: Data from P3 BE SURE trial (NCT03412747) for psoriasis in Q4 2019 (UCB) – Jul 26, 2019 – H1 2019 Results  
[Screenshot]

 

bimekizumab (UCB4940) / UCB
UCB half year report 2019: UCB’s strong performance enables continued investment into future growth drivers (PharmiWeb) – Jul 25, 2019 – “In March and April, the second and the third phase 3 program with bimekizumab – in psoriatic arthritis and in axial Spondyloarthitis – were initiated, slightly earlier than planned. First topline results are expected at the end of 2021.”

 

Imraldi (adalimumab biosimilar) / Biogen, Merck (MSD), Samsung
FDA approves Samsung Bioepis’ Hadlima (adalimumab-bwwd) (Businesswire) – Jul 24, 2019 – “Samsung Bioepis…announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.”

 

ANB019 / AnaptysBio
ANB019 US pricing projection: $50,000/year (Credit Suisse) – Jul 29, 2019 – A subscription to Thomson ONE is required to gain full access to report 67407578; Page no: 6; REPORT TITLE: “Anaptysbio Inc ANAB: Bull versus bear debate”; AUTHOR: Auster, Martin, et al; DATE: 05/29/2019

 

Otezla (apremilast) / Celgene
Bristol-Myers confident with on-time OK of Celgene deal in Europe (SeekingAlpha) – Jul 23, 2019 – “BMY has agreed to divest CELG’s Otezla (apremilast) in order to receive a timely thumbs-up in the U.S.”

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Ilumya sales projection: $30M in FY2020, $110M in FY2021 and $475M peak (Morgan Stanley)- Jul 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67624534; Page no: 22, 12; REPORT TITLE: “Sun Pharmaceutical Industries: Set to shine – double upgrade to OW”; AUTHOR: Baisiwala, Sameer, et al; DATE: 07/14/2019

Otezla (apremilast) / Celgene
Otezla sales projection: $1.5B in US and $400M ex-US in 2019 (Jefferies) – Jul 22, 2019 – A subscription to Thomson ONE is required to gain full access to report 67603525; Page no: 31; REPORT TITLE: “Q2 EPS thoughts: AMGN, BIIB, CELG, GILD, ALXN, REGN, VRTX, AMRN and lots more”; AUTHOR: Yee, Michael, et al; DATE: 07/09/2019

No Comments

Post a Comment

Comment
Name
Email
Website